Home > Neurology > ECTRIMS 2019 > Towards a Comprehensive Assessment of MS Course > Novel ways to assess MS

Novel ways to assess MS

Expert
Dr Megan Sokolowski (Cleveland Clinic, OH, USA), Prof. Jeremy Hobart (University of Plymouth, United Kingdom)
Conference
ECTRIMS 2019
Trial
Phase 3, SPI2

Until recently, MS clinical trial endpoints have focused primarily upon measures of disease activity instead of patient-reported outcome measures (PROMs). There is a growing desire, especially from regulatory authorities, to include endpoints measuring disease activity as seen from the patient’s perspective.

MS performance test

The Multiple Sclerosis Performance Test (MSPT) is a novel, iPad®-based disability assessment tool that resembles the Multiple Sclerosis Functional Composite (MSFC) [1,2]. It includes a computer-adapted version of Neuro-QoL, and 4 self-administered neuroperformance tests, providing measurements of walking speed, manual dexterity, low contrast visual acuity, and cognitive processing speed.

Convergent validity studies comparing the MSPT and MSFC subtests have been published [3] or are under editorial review. MSPT is being used as part of the international MS-PATHS network of MS centres, where over 40,000 ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on